Microbiome in RCC – A systematic review of the literature
Year: 2024
Type: review
Study design: Systematic Review
Abstract: Background: Renal cell carcinoma (RCC) accounts for approximately 90% of kidney cancers, with a significant percentage of patients presenting with metastatic disease. Recent evidence suggests a notable role of the human microbiome in the onset, progression, and therapeutic outcomes of RCC. Objective: This systematic review aims to synthesise current knowledge on the association between the microbiome and RCC, focusing on pathogenesis, progression, and response to therapy. Methods: Complying with PRISMA guidelines, databases including PubMed, Embase, and Web of Science were searched for relevant studies up to December 7, 2023. The inclusion criterion was English-language articles that discussed RCC in relation to the microbiome of any body region. Screening was performed in a two-phase manner by three authors. Results: From 570 articles, 65 met the inclusion criteria. The gut microbiome (GM) emerged as a potential RCC pathogenesis driver, with certain bacteria associated with increased or decreased risk. Studies have also demonstrated that antibiotics and other medications can influence RCC therapeutic outcomes, reducing the effectiveness of immune-modulating therapies. Conclusions: While multiple bacterial species and antibiotics have been implicated in influencing RCC, further research is necessary to elucidate these relationships and investigate the efficacy of microbiome modulation on therapy effectiveness. Findings underscore the significant impact of the microbiome on RCC, suggesting the potential for microbiota-targeted therapeutics.
Source: Kidney Cancer
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4404895580